Display options
Cite
Mondello P, Pitini V, Barresi V, et al. Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Exp Hematol Oncol. 2016;5:1doi: 10.1186/s40164-015-0030-1.
Mondello, P., Pitini, V., Barresi, V., Brea, E. J., Di Mirto, C., Arrigo, C., Cuzzocrea, S., & Mian, M. (2015). Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Experimental hematology & oncology, 51. https://doi.org/10.1186/s40164-015-0030-1
Mondello, Patrizia, et al. "Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent." Experimental hematology & oncology vol. 5 (2015): 1. doi: https://doi.org/10.1186/s40164-015-0030-1
Mondello P, Pitini V, Barresi V, Brea EJ, Di Mirto C, Arrigo C, Cuzzocrea S, Mian M. Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent. Exp Hematol Oncol. 2016 Jan 06;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015. PMID: 26740908; PMCID: PMC4702294.
Copy Download .nbib Format: NLM
Share it on

Exp Hematol Oncol. 2016 Jan 06;5:1. doi: 10.1186/s40164-015-0030-1. eCollection 2015.

Extranodal diffuse large B-cell lymphoma with monoclonal gammopathy: an aggressive and primary refractory disease responding to an immunomodulatory agent.

Experimental hematology & oncology

Patrizia Mondello, Vincenzo Pitini, Valeria Barresi, Elliott Joseph Brea, Cristian Di Mirto, Carmela Arrigo, Salvatore Cuzzocrea, Michael Mian

Affiliations

  1. Department of Human Pathology, University of Messina, Via Consolare Valeria, 98100 Messina, Italy ; Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy ; Lymphoma Department, Lymphoma Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY USA.
  2. Department of Human Pathology, University of Messina, Via Consolare Valeria, 98100 Messina, Italy.
  3. Molecular Pharmacology and Chemistry Program, Sloan-Kettering Institute, New York, NY USA ; Weill Cornell Medical College, New York, NY USA.
  4. Department of Internal Medicine, University of Messina, Messina, Italy.
  5. Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
  6. Department of Hematology and CBMT, Ospedale di Bolzano, Bolzano, Italy ; Universitätsklinik für Innere Medizin V, Hämatologie and Onkologie, Innsbruck, Austria.

PMID: 26740908 PMCID: PMC4702294 DOI: 10.1186/s40164-015-0030-1

Abstract

BACKGROUND: Although the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL) has been improved by the addition of rituximab to standard chemotherapy, almost one-third fails or relapses after first line treatment. The presence of monoclonal gammopathy (MG) is a known adverse prognostic factor for DLBCL. Because this subset of patients does not benefit from R-CHOP, new therapeutic options are required. Herein, we report the first case of extranodal DBCL of the lung with a concomitant MG who achieved a long lasting complete remission with lenalidomide.

CASE PRESENTATION: The 73-year-old male patient presented with lateral cervical lymphadenopathy, B symptoms, lactate dehydrogenase and beta2-microglobulin elevation. Computed tomography (CT) showed mediastinal lymphadenopathy and bilateral lung involvement. Biopsy of both disease locations revealed the presence of DLBCL. Successive bone marrow trephine biopsy proved the presence of concordant DLBCL involvement. At the time of diagnosis, a MG was present as well. The patient did not respond to the standard treatments, and subsequently underwent lenalidomide 25 mg/m(2) days 1-21 q28 plus dexamethasone 40 mg days 1-4, 9-12 e 17-20. This therapeutic regimen was efficacious and safe as salvage therapy in extranodal DBCL with a MG. Furthermore, we observed a close association between DLBCL response to therapy and MG levels, suggesting that the amount of M-protein might be a surrogate marker of disease response.

CONCLUSION: Although DLBCL associated with MG does not respond properly to the standard treatments, it is highly sensitive to lenalidomide, which is why we endorse its role as treatment of choice in this subset of patients. In addition, MG levels appear to correlate with tumor burden, suggesting that it might be a useful marker of disease response. Prospective trials to validate these observations are warranted.

Keywords: Diffuse large B-cell lymphoma; Lenalidomide; Monoclonal gammopathy; Serum free light chain

References

  1. Am J Hematol. 1991 Mar;36(3):171-5 - PubMed
  2. Blood. 2004 Jan 1;103(1):275-82 - PubMed
  3. Br J Haematol. 2013 Feb;160(4):487-502 - PubMed
  4. Histopathology. 2003 Dec;43(6):509-28 - PubMed
  5. Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9991-6 - PubMed
  6. Blood. 1997 Feb 15;89(4):1413-20 - PubMed
  7. Mod Pathol. 2005 Jun;18(6):806-15 - PubMed
  8. Ann Otol Rhinol Laryngol. 1999 Jan;108(1):95-9 - PubMed
  9. Leukemia. 2012 Nov;26(11):2326-35 - PubMed
  10. Science. 2010 Mar 12;327(5971):1345-50 - PubMed
  11. Ann Hematol. 2014 Nov;93(11):1867-77 - PubMed
  12. Leuk Res. 2011 Mar;35(3):380-6 - PubMed
  13. Cancer. 2011 Nov 15;117(22):5058-66 - PubMed
  14. Am J Hematol. 2014 Apr;89(4):417-22 - PubMed
  15. N Engl J Med. 2008 Nov 27;359(22):2313-23 - PubMed
  16. N Engl J Med. 2007 Nov 22;357(21):2133-42 - PubMed
  17. N Engl J Med. 2010 Apr 15;362(15):1417-29 - PubMed
  18. Br J Haematol. 2002 Dec;119(3):622-8 - PubMed
  19. CA Cancer J Clin. 2013 Jan;63(1):11-30 - PubMed
  20. Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13520-5 - PubMed
  21. PLoS One. 2014 Apr 04;9(4):e93903 - PubMed
  22. Nature. 2000 Feb 3;403(6769):503-11 - PubMed
  23. J Clin Oncol. 2011 Apr 20;29(12):1620-6 - PubMed
  24. Diagn Cytopathol. 2002 Oct;27(4):218-22 - PubMed
  25. Ann Oncol. 2011 Jul;22(7):1622-7 - PubMed
  26. Leuk Lymphoma. 2013 Sep;54(9):1898-907 - PubMed
  27. Science. 2014 Jan 17;343(6168):305-9 - PubMed
  28. Leuk Res. 2006 Jul;30(7):849-58 - PubMed
  29. N Engl J Med. 2014 Sep 4;371(10):906-17 - PubMed
  30. Blood. 1998 Apr 1;91(7):2501-7 - PubMed
  31. Blood. 2003 Oct 1;102(7):2638-41 - PubMed
  32. N Engl J Med. 2007 Nov 22;357(21):2123-32 - PubMed
  33. Lancet Oncol. 2014 Nov;15(12):e538-48 - PubMed
  34. N Engl J Med. 2002 Jun 20;346(25):1937-47 - PubMed
  35. Am J Med Sci. 1996 Sep;312(3):136-7 - PubMed
  36. Br J Haematol. 2014 Jan;164(2):233-44 - PubMed

Publication Types

Grant support